Investment
Features
FeesSafety
Academy
More
Pluang+

KNG ETF offers high yield via covered calls but underperforms NOBL over 8 years.

Market News
25 May 2026
24/7 Wall Street
View Source
Neutral
pluang ai news

The FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) uses covered calls on Dividend Aristocrats stocks to deliver an 8.6% yield, appealing to retirees seeking income. However, this strategy caps upside gains, causing KNG to underperform the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) by about 1.75% annually over eight years. While KNG provides steady monthly income, it sacrifices long-term total returns and charges higher fees. Investors needing monthly cash flow might find KNG suitable, but those prioritizing growth should prefer NOBL to benefit from compounding dividends and price appreciation.

More News (JNJ)

FTSE 100 dips as miners fall on China slowdown; PayPal jumps on $53B bid from Stripe and Advent

FTSE 100 dips as miners fall on China slowdown; PayPal jumps on $53B bid from Stripe and Advent

The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...

Market News
Neutral
6 hours ago
Soft CPI eases Fed rate hike odds, PPI report today to confirm inflation trend and guide markets.

Soft CPI eases Fed rate hike odds, PPI report today to confirm inflation trend and guide markets.

US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...

Market News
Bullish
7 hours ago
DARZALEX sales hit $4.2B in Q2 2026, boosting Genmab royalties from J&J worldwide sales.

DARZALEX sales hit $4.2B in Q2 2026, boosting Genmab royalties from J&J worldwide sales.

Genmab announced that DARZALEX (daratumumab) achieved net trade sales of $4.207 billion globally in Q2 2026, with $2.435 billion from the U.S. and $1.772 billion from other regions. Genmab earns royalties on these worldwide sales through its licensin...

Company Fundamentals
Bullish
8 hours ago
Johnson & Johnson Q2 earnings expected to rise, stock hits record high amid strong outlook

Johnson & Johnson Q2 earnings expected to rise, stock hits record high amid strong outlook

Johnson & Johnson is set to report its Q2 2026 earnings with analysts expecting earnings per share of $2.85 and revenue of $25.02 billion, both higher than the previous year. The company has a strong track record of beating revenue estimates and its ...

Company Fundamentals
Bullish
18 hours ago
Johnson & Johnson set to report Q2 earnings with raised price targets and dividend insights.

Johnson & Johnson set to report Q2 earnings with raised price targets and dividend insights.

Johnson & Johnson will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.06 billion, up from last year. Analysts from RBC Capital and TD Cowen have maintained positive ratings and raised price ...

Company Fundamentals
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App